




EHRA
European Heart
Rhythm Association
European Society of Cardiology

Symposium with international participation
"HIGHLIGHTS IN CARDIOVASCULAR DISEASES"

ABSTRACT BOOK



04-06 November 2022,
h. DoubleTree by Hilton, Skopje, North Macedonia

CONTENT

WELCOME ADDRESS.....	v
COMMITTEES.....	vi
ABSTRACTS:	
MULTIDISCIPLINARY APPROACH TO CARDIOVASCULAR PREVENTION: CHALLENGES AND CHOICES.....	1
ORAL POSTER SESSION.....	5
NONINVASIVE IMAGING IN THE CONTINUUM OF CORONARY ARTERY DISEASE: FROM ATHEROSCLEROSIS TO HEART FAILURE..	12
EHRA ENDORSED SYMPOSIUM ATRIAL FIBRILLATION – ABLATION PROCEDURES: PVI– HOW TO START A NEW ABLATION CENTER?....	14
ACUTE HEART FAILURE: CHALLENGES AND CHOICES.....	16
STRUCTURAL AND ENDOVASCULAR INTERVENTIONS: INTERVENTIONAL CARDIOLOGY.....	19
CHRONIC HEART FAILURE: GUIDELINE APPROACH, IMAGING AND PROGNOSIS.....	22
CORONARY ARTERY DISEASE: INTERVENTIONAL CARDIOLOGY.....	29
INTERESTING CASES FROM THE ECHO/VASCULAR LAB.....	33
NEW GUIDELINES 2021/2022.....	38
JOIN SESSION OF THE MACEDONIAN SOCIETY OF CARDIOLOGY AND ASSOCIATION OF CARDIO-THORACIS, VASCULAR AND ENDOVASCULAR SURGERY: HIGHLIGHTS IN INFECTIVE ENDOCARDITIS.....	41
POSTER SESSION.....	46
AUTHOR INDEX.....	95

COMMITTEES

President of the Symposium

Marjan Bosevski

Scientific Committee

Irena Mitevaska

Jorgo Kostov

Lidija Poposka

Valentina Andova

Elizabeta Srbinovska Kostovska

International Committee

David Jimenez (Spain)

Vasil Traykov (Bulgaria)

Zviad Kipiani (Georgia)

Jadranka Stojanovska (USA)

Hatem Soleman (UK)

Lilly Stojanovska (UAE)

Gianluca Pontone (Italy)

Ahmet Yildiz (Turkey)

Alessia Gimelli (Italy)

Milan Nedeljkovic (Serbia)

SGLT2I IN PATIENT WITH CABG, METABOLIC SYNDROME AND T2DM

S. Dokuzova¹, M. Bajdevska Spirkovska², G. Kamcheva Mihailova³

Clinical Hospital Shtip,

General Hospital Kumanovo, N.R. Macedonia

Introduction: SGLT2i are associated with a reduction in adverse major cardiac and cerebrovascular events especially in patients with heart failure and T2DM. Effect and safety in treatment using this new drugs results in a greater reduction in HBA1C, TT, FPG, PPG, SBP, BMI, LDL and is recommended in a patient with poor glycoregulation after a previously performed aorto-coronary bypass and metabolic syndrome (obesity, hypertension, diabetes, hypertriglyceridemia).

Aim: The high potential of mechanism of SGLT2i in patient with heart failure, T2DM and many comorbidities reduce the risk for hospitalization and cardiovascular mortality.

Material and methods: Male patient 53, with T2DM more than 3 years, CABGX5 before 4 months on a therapy with Insulin Humulin N 26+12, HBA1C=15%, poor glycoregulation, FPG=16,6...trig=3,6, creatinin=96, TT=110, GFR=81, urine=normal, TA 150/100, HR/112, EF=44% with fatigue, ringing in the ears and dizziness came at internal department. The therapy was changed with: Tbl. Siofor 2x1000, Insulin Ryzodeg 24ie+22ie s.c. Tbl. Jardiance+statin, beta blocker, antihypertensive and antiagregation drugs. It was recommended to take more care of hygiene of the genitourinary tract and diet.

Results: After 1 month patient didn't show up on control, after 6 months was done another echocardiography EF=47%, fpg=8,8, trig=1,9, creatinin=90, hba1c=11,37%, tt=106, TA 135/90, subjectively feels better and has no new hospitalizations.

Conclusion: SGLT2i improved endothelial function, glycoregulation, contractility, reduction of blood pressure, cardiac metabolism, reduction of albuminuria, glomerular pressure and renal protection. All these characteristics place it highly in the treatment of patients with HF, T2DM and many comorbidities.

Key words: Empagliflozine, heart failure, diabetes mellitus type 2